reslizumab

Home
Ligands
reslizumab

GtoPdb Ligand ID: 8091

reslizumab is an approved drug (EMA & FDA (2016))

Comment: Reslizumab is a monoclonal antibody with antiinflammatory action. It is designed to treat eosinophil-driven inflammatory conditions of the airways, skin and gastrointestinal tract [1,4].

View more information in the IUPHAR Pharmacology Education Project: reslizumab

Immunopharmacology Comments
Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. Consequently survival and activity of eosinophils are reduced, lowering exacerbation rates and improving lung function in patients with severe eosinophilic asthma.

Immunopharmacology Comments

Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. Consequently survival and activity of eosinophils are reduced, lowering exacerbation rates and improving lung function in patients with severe eosinophilic asthma.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Asthma	Disease Ontology: DOID:2841 OMIM: 600807	Approved therapeutic as maintenance treatment for asthma in combination with other asthma medications.